A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive)

Inclusion Criteria: * Must be at least 20 years of age at screening. * Signed and dated written informed consent in accordance with Good Clinical Practice(GCP) and local legislation prior to admission to the trial. * Pathologically documented, locally-advanced or metastatic malignancy with previously identified activating Neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) or Kirsten rat sarcoma viral oncogene homologue (KRAS) mutation based on local test. * Provision of archival tumor tissue, if available, to confirm retrospectively NRAS or KRAS mutation status and for biomarker assessment. * Willingness to undergo pre- and on-treatment tumour biopsies for pharmacodynamics and biomarker assessment. Patients can be enrolled without tumour biopsy upon agreement between the Investigator and the Sponsor if tumour biopsy is not feasible (Apply only to study site which agreed to conduct biopsy). * Must have either progressed despite appropriate prior standard therapies or for whom no standard therapy exists for their tumour type and disease stage * Must have at least one target lesion that can be measured per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 * Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Further inclusion criteria apply. Exclusion Criteria: * Previous anticancer chemotherapy within 3 weeks of the first administration of trial drug. Previous anticancer hormonal treatment or anticancer immunotherapy wi…